

MAUNA KEA TECHNOLOGIES REPORTS RECORD ATTENDANCE AT ICCU 2015 AND AT THE ASSOCIATED POST-GRADUATE COURSE ON ENDOMICROSCOPY

- **300 physicians and surgeons gathered in Lisbon at the International Conference of Cellvizio Users to discuss advancements and benefits of endomicroscopy in multiple medical and surgical indications**
 - **First post-graduate course organized and chaired by Pr. Satish Singh from Boston University**

PARIS, France – April 15, 2015 – Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today the success record attendance of the 7th edition of the International Conference of Cellvizio Users (ICCU 2015). About 300 physicians and surgeons gathered in Lisbon, Portugal, from April 10 to April 12 for two days of intense training and discussions on the wide number of clinical and pre-clinical indications of Confocal Laser Endomicroscopy in research, medicine and surgery. Earlier this year, an 18 member scientific committee, chaired by Pr. Jean-Paul Galmiche from Nantes University Hospital, selected best abstracts among the large quantity of work submitted, to create a dense program with multiple plenary and breakout sessions.

"This 7th edition of ICCU, the largest and most multi-disciplinary one to date, reflected the growing importance of confocal laser endomicroscopy in many fields of medicine and surgery" said Dr Gregory Y. Lauwers, Vice Chairman of Pathology and Director of Gastrointestinal Pathology at the Massachusetts General Hospital in Boston and co-Chairman of ICCU 2015, "The fast growing collaboration between pathologists and clinical users of endomicroscopy worldwide is patent and key to drive adoption of optical biopsy, through training and joint patient management decisions."

For the first-time, a post-graduate course was held in parallel of ICCU and could barely accommodate the number of attendees who listened to leaders in their field discuss the clinical use of endomicroscopy for a wide range of gastroenterological applications: characterization of pancreatic cysts and biliary strictures, management of patients with Inflammatory Bowel Disease, Barrett's Esophagus and early squamous cell carcinoma to name a few.

"ICCU 2015 was, once again, a clear expression of the growing role of endomicroscopy in multiple applications, enabling physicians and now surgeons from many specialties to have a more efficient workflow for the benefit of the patient", concludes Sacha Loiseau, CEO and founder of Mauna Kea Technologies.

The full scientific program of ICCU 2015 can be downloaded [here](#)

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy and optical biopsy. The company designs, develops and markets innovative tools to visualize and detect cell abnormalities in real time during standard endoscopy procedures. The company's flagship product, Cellvizio®, a probe needle based Confocal Laser Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with high-resolution cellular imaging of internal tissues. Large-scale, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early forms of diseases and make immediate treatment decisions. Designed to help physicians in their diagnoses, provide patients with better treatment and reduce hospital costs, the Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k) clearance from the United States Food and Drug Administration and CE Marking in the European Union for use in the gastrointestinal tract and the urinary and respiratory systems, for endoscopic exploration of the biliary and pancreatic ducts and for fine-needle aspiration procedures. Cellvizio has also obtained SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com



Mauna Kea Technologies

Eric Cohen

Vice-President Finance

Tel. : +33 (0)1 70 08 09 70

investor-vpf@maunakeatech.com

France & Europe

NewCap - Investor Relations & Financial Communication

Florent Alba / Pierre Laurent

Tel. : +33 (0)1 44 71 94 94

maunakea@newcap.fr